|Bid||5.13 x 0|
|Ask||5.27 x 0|
|Day's Range||5.12 - 5.28|
|52 Week Range||3.51 - 28.14|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO, CANADA / ACCESSWIRE / June 22, 2020 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company") today announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide (PEA), or FSD201.
“Cannabis stores and cannabis producers” are on Ontario’s list of workplaces. It’s a win for a sector that was facing tough times long before COVID-19 threatened the global economy.
FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) has launched its online ordering system for the direct fulfillment of medicinal cannabis orders. Clients having a prescription from a medical practitioner or a registration number with Health Canada can now place an order online for dried cannabis on FVPharma.com. FSD Pharma subsidiary FV Pharma will handle the system. "The launch of a functional online ordering portal […]The post FSD Pharma Launches Online System for Medicinal Cannabis Orders appeared first on Market Exclusive.